Metoclopramide Accord (Metoclopramide Hydrochloride)

Metoclopramide is used to treat conditions related to nausea, gastric motility disorders, and reflux.

• Nausea and vomiting: alleviates symptoms in postoperative, chemotherapy‑induced, or other acute settings by blocking dopamine receptors in the chemoreceptor trigger zone.
• Gastroparesis: improves gastric emptying and reduces related discomfort by enhancing gastrointestinal motility through increased acetylcholine release.
• Gastro‑oesophageal reflux disease: decreases reflux episodes by promoting faster gastric emptying and reducing gastric stasis.
• Migraine‑associated nausea: controls nausea accompanying migraine attacks via central anti‑emetic action.

• Metoclopramide exerts its effect primarily by antagonizing dopamine D2 receptors in the chemoreceptor trigger zone of the medulla, which suppresses the vomiting reflex. Concurrently, it blocks presynaptic dopamine receptors in the gastrointestinal tract, leading to increased release of acetylcholine; the heightened cholinergic activity stimulates smooth‑muscle contraction, thereby accelerating gastric emptying and improving motility. These combined central and peripheral actions make metoclopramide effective for both anti‑emetic and pro‑kinetic purposes.

Metoclopramide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Drowsiness: a feeling of sleepiness that may affect concentration.
• Fatigue: persistent tiredness that can reduce physical activity.
• Restlessness or akathisia: an uncomfortable urge to move, sometimes accompanied by anxiety.
• Gastrointestinal upset: includes nausea, diarrhea, abdominal cramps, or mild indigestion.

Serious or Rare Side Effects

• Extrapyramidal reactions: muscle rigidity, tremor, dystonia, or other involuntary movements.
• Tardive dyskinesia: potentially irreversible, repetitive facial or tongue movements after prolonged use.
• Neuroleptic malignant syndrome: rare but life‑threatening condition with high fever, severe muscle rigidity, and autonomic dysfunction.
• Hyperprolactinemia: elevated prolactin causing galactorrhea, menstrual irregularities, or sexual dysfunction.

When prescribing Metoclopramide, clinicians should consider several safety and handling precautions.

• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding: assess risk as the drug may be excreted in human milk.
• Renal impairment: dose adjustment may be required in patients with reduced renal function.
• Elderly: increased susceptibility to extrapyramidal effects; monitor closely.
• Drug interactions: avoid concomitant use with other dopamine antagonists when possible.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Metoclopramide can affect the activity of several other medicines; notable interactions are listed below.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol, chlorpromazine): additive dopamine blockade may increase extrapyramidal risk.
• MAO inhibitors: combined use can potentiate hypertensive reactions.
• CYP2D6 substrates (e.g., codeine, tramadol): metoclopramide may inhibit metabolism, raising plasma levels.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation.
• Anticholinergic agents: opposing effects on gastrointestinal motility.
• Serotonergic drugs (e.g., SSRIs, triptans): potential for serotonin syndrome, though rare.